Clinical Trial ProgressAn independent DSMB recommended continuation of the NEUTRALIZE-AKI trial with no safety concerns, noting a potential efficacy signal.
Financial StrategyThe company raised net proceeds of ~$7.6M in two registered direct offerings, which could extend cash runway.
Revenue GrowthICU's slightly better-than-expected 2Q25 revenue was driven by the addition of three new pediatric hospital customers, including Texas Children’s Hospital, a major pediatric center.